𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

✍ Scribed by Bokemeyer, C.; Bondarenko, I.; Makhson, A.; Hartmann, J. T.; Aparicio, J.; de Braud, F.; Donea, S.; Ludwig, H.; Schuch, G.; Stroh, C.; Loos, A. H.; Zubel, A.; Koralewski, P.

Book ID
127227400
Publisher
American Society of Clinical Oncology
Year
2009
Tongue
English
Weight
201 KB
Volume
27
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Fluorouracil, Leucovorin, and Oxaliplati
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
✍ Bokemeyer, C.; Bondarenko, I.; Makhson, A.; Hartmann, J. T.; Aparicio, J.; de Br πŸ“‚ Article πŸ“… 2009 πŸ› American Society of Clinical Oncology 🌐 English βš– 201 KB

## Purpose This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation sta

Capecitabine plus oxaliplatin (XELOX) ve
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
✍ Michel Ducreux; Jaafar Bennouna; Mohamed Hebbar; Marc Ychou; GΓ©rard Lledo; Thier πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 440 KB

## Abstract A regimen consisting of 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) is widely used in France in the first‐line treatment of metastatic colorectal cancer (MCRC). The aim of our study was to demonstrate the non‐inferiority of capecitabine plus oxaliplatin (XELOX) __versus__ FOLF